TOI Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of -13.15% compared to The Oncology Institute's net margin of 8.61%. The Oncology Institute's return on equity of -220.55% beat Encompass Health's return on equity of 17.79%.

The Oncology Institute has a consensus price target of --, signalling upside risk potential of 75.44%. On the other hand Encompass Health has an analysts' consensus of $117.25 which suggests that it could grow by 15.77%. Given that The Oncology Institute has higher upside potential than Encompass Health, analysts believe The Oncology Institute is more attractive than Encompass Health.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Encompass Health has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.77%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.63% to investors and pays a quarterly dividend of $0.17 per share. The Oncology Institute pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Oncology Institute quarterly revenues are $100.3M, which are smaller than Encompass Health quarterly revenues of $1.4B. The Oncology Institute's net income of -$13.2M is lower than Encompass Health's net income of $120.9M. Notably, The Oncology Institute's price-to-earnings ratio is -- while Encompass Health's PE ratio is 22.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.22x versus 1.93x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD has a net margin of -13.15% compared to The Oncology Institute's net margin of -156.54%. The Oncology Institute's return on equity of -220.55% beat Kindly MD's return on equity of -201.03%.

The Oncology Institute has a consensus price target of --, signalling upside risk potential of 75.44%. On the other hand Kindly MD has an analysts' consensus of -- which suggests that it could fall by --. Given that The Oncology Institute has higher upside potential than Kindly MD, analysts believe The Oncology Institute is more attractive than Kindly MD.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kindly MD has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute pays -- of its earnings as a dividend. Kindly MD pays out -- of its earnings as a dividend.

The Oncology Institute quarterly revenues are $100.3M, which are larger than Kindly MD quarterly revenues of $647.9K. The Oncology Institute's net income of -$13.2M is lower than Kindly MD's net income of -$1M. Notably, The Oncology Institute's price-to-earnings ratio is -- while Kindly MD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.22x versus 3.19x for Kindly MD. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of -13.15% compared to The Oncology Institute's net margin of 6.07%. The Oncology Institute's return on equity of -220.55% beat Pediatrix Medical Group's return on equity of -12.67%.

The Oncology Institute has a consensus price target of --, signalling upside risk potential of 75.44%. On the other hand Pediatrix Medical Group has an analysts' consensus of $18.36 which suggests that it could grow by 26.69%. Given that The Oncology Institute has higher upside potential than Pediatrix Medical Group, analysts believe The Oncology Institute is more attractive than Pediatrix Medical Group.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.466%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute pays -- of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend.

The Oncology Institute quarterly revenues are $100.3M, which are smaller than Pediatrix Medical Group quarterly revenues of $502.4M. The Oncology Institute's net income of -$13.2M is lower than Pediatrix Medical Group's net income of $30.5M. Notably, The Oncology Institute's price-to-earnings ratio is -- while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.22x versus 0.60x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of -13.15% compared to The Oncology Institute's net margin of 4.12%. The Oncology Institute's return on equity of -220.55% beat US Physical Therapy's return on equity of 3.86%.

The Oncology Institute has a consensus price target of --, signalling upside risk potential of 75.44%. On the other hand US Physical Therapy has an analysts' consensus of $108.33 which suggests that it could grow by 49.71%. Given that The Oncology Institute has higher upside potential than US Physical Therapy, analysts believe The Oncology Institute is more attractive than US Physical Therapy.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.634%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.45% to investors and pays a quarterly dividend of $0.45 per share. The Oncology Institute pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

The Oncology Institute quarterly revenues are $100.3M, which are smaller than US Physical Therapy quarterly revenues of $180.4M. The Oncology Institute's net income of -$13.2M is lower than US Physical Therapy's net income of $7.4M. Notably, The Oncology Institute's price-to-earnings ratio is -- while US Physical Therapy's PE ratio is 39.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.22x versus 1.62x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.